IFG Advisors LLC Sells 57 Shares of Eli Lilly and Company (NYSE:LLY)

IFG Advisors LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 804 shares of the company’s stock after selling 57 shares during the period. IFG Advisors LLC’s holdings in Eli Lilly and Company were worth $621,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Kohmann Bosshard Financial Services LLC boosted its stake in Eli Lilly and Company by 5.9% during the fourth quarter. Kohmann Bosshard Financial Services LLC now owns 413 shares of the company’s stock valued at $319,000 after buying an additional 23 shares during the period. Smartleaf Asset Management LLC lifted its stake in Eli Lilly and Company by 16.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 8,896 shares of the company’s stock worth $6,885,000 after purchasing an additional 1,230 shares during the last quarter. Maia Wealth LLC lifted its stake in Eli Lilly and Company by 4.7% during the fourth quarter. Maia Wealth LLC now owns 2,528 shares of the company’s stock worth $2,043,000 after purchasing an additional 113 shares during the last quarter. Cape Investment Advisory Inc. lifted its stake in Eli Lilly and Company by 17.1% during the fourth quarter. Cape Investment Advisory Inc. now owns 192 shares of the company’s stock worth $148,000 after purchasing an additional 28 shares during the last quarter. Finally, Purkiss Capital Advisors LLC bought a new stake in Eli Lilly and Company during the fourth quarter worth about $452,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 1.7 %

Shares of NYSE:LLY opened at $920.44 on Friday. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53. The stock’s 50-day moving average is $814.88 and its 200 day moving average is $848.69. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The company has a market cap of $872.73 billion, a PE ratio of 78.60, a P/E/G ratio of 1.40 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its board has authorized a share repurchase program on Monday, December 9th that permits the company to buyback $15.00 billion in outstanding shares. This buyback authorization permits the company to buy up to 2% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.65%. Eli Lilly and Company’s dividend payout ratio is 51.24%.

Analysts Set New Price Targets

Several brokerages have issued reports on LLY. Wolfe Research began coverage on Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price target for the company. Citigroup dropped their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research note on Friday, January 17th. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Finally, Wells Fargo & Company dropped their price target on Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,000.28.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.